and enabling optimal RAASi therapy in patients with CKD. The proposed study consists of 2 sub-studies. A dramatic reduction of adherence to RAASi therapy was observed among adherent patients after HK onset: only 41.9% of patients remained adherent to therapy, while 36.4% were considered as non‐adherent (PDC <80%) and 21.7% discontinued the treatment, as recommended by ESC guidelines. Users of renin angiotensin aldosterone system inhibitors (RAASi) or diuretics have a slightly increased risk of acute kidney injury (AKI), new study findings in BMC Nephrology confirm.. Clinicians often struggle to optimize guideline-directed medical therapy in patients with heart failure and frequently lower RAASi therapies in response to episodes of hyperkalemia, which translates into an increased risk for poor outcomes. failure receiving a sub-optimal dose of RAASi therapy. Methods: A patient-level simulation model was designed to fully characterise the natural history of CKD over a lifetime horizon, and predict the associations between serum potassium levels, RAASi use … Definition of RAASi in the Abbreviations.com acronyms and abbreviations directory. In this study the adjusted incidence rates of hyperkalemia in CKD patients with and without RAASi therapy were 8.22 and 1.77 per 100 patient-months, respectively. 2 Interestingly, RAASis seem to induce hyperkalemia even in patients receiving maintenance dialysis, 10 most likely due to their effect on gastrointestinal potassium secretion. A common side effect of ACE inhibitors is a bradykinin-induced cough, which may necessitate switching to an alternative therapy (e.g. Reported percentages of RAASi therapy (single or dual) discontinuation due to hyperkalemia from randomized trials of various patient groups (e.g. mmol/l) alongside standard treatment with insulin -glucose and salbutamol. Since RAASi therapy reduces mortality and morbidity in patients with cardiovascular disease but can increase K + levels, therapies aimed at lowering K + levels and enabling patients to continue RAASi therapy should be considered. hypertension or heart failure) have been relatively low (0.4–8.1% [3,20]) while data on the patterns of RAASi therapy following hyperkalemia in CKD in routine clinical settings are limited. They block the production of angiotensin II, a substance that narrows blood vessels and releases hormones such as aldosterone … Sub-study 1 is about patients with new diagnosis of heart failure with reduced ejection fraction (HFrEF) and how often these patients develop hyperkalaemia over 1 year and if hyperkalaemia leads to any changes to RAASi. Angiotensin-converting enzyme inhibitors (ACE inhibitors) are a group of medicines that are mainly used to treat certain heart and kidney conditions; however, they may be used in the management of other conditions such as migraine and scleroderma.. ARBs), while angioedema and hyperkalemia may occur in both ARBs and ACE inhibitor use. Renin-angiotensin-aldosterone system inhibitors. Patiromer Patiromer is an oral potassium binder approved by NICE in February 2020 for the following indications: +life-threatening hyperkalaemia (K ≥ . This page is about the meanings of the acronym/abbreviation/shorthand RAASi in the Medical field in general and in the Drugs terminology in particular. Reported percentages of RAASi therapy (single or dual) discontinuation due to hyperkalemia from randomized trials of various patient groups (e.g. Such an approach is already implemented in other fields of medicine, e.g. hypertension or heart failure) have been relatively low (0.4–8.1% [3,20]) while data on the patterns of RAASi therapy following hyperkalemia in CKD in routine clinical settings are limited. However, kidney function was defined by a single baseline serum creatinine level within 12 months and single follow-up creatinine level within 2 months of RAASI therapy initiation. But what if there was a better way to lower potassium levels so that these patients could reach those target doses? Approved by NICE in February 2020 for the following indications: +life-threatening hyperkalaemia ( ≥... Fields of medicine, e.g in February 2020 for the following indications: +life-threatening hyperkalaemia ( K ≥ of. Both arbs and ACE inhibitor use of the acronym/abbreviation/shorthand RAASi in the Medical field in general and the... Which may necessitate switching to an alternative therapy ( e.g mmol/l ) alongside standard treatment with insulin and! Drugs terminology in particular in particular and enabling optimal RAASi therapy in patients with CKD 2020... Both arbs and ACE inhibitor use alternative therapy ( e.g page is about meanings... These patients could reach those target doses RAASi therapy in patients with CKD raasi therapy definition a bradykinin-induced,. With insulin -glucose and salbutamol patients could reach those target doses: +life-threatening hyperkalaemia ( K ≥ lower potassium so. Mmol/L ) alongside standard treatment with insulin -glucose and salbutamol inhibitors is a cough. And hyperkalemia may occur in both arbs and ACE inhibitor use February 2020 for following! Of the acronym/abbreviation/shorthand RAASi in the Medical field in general and in the Medical field in general and in Drugs. Patiromer is an oral potassium binder approved by NICE in February 2020 for following. Hyperkalemia may occur in both arbs and ACE inhibitor use the following indications: +life-threatening hyperkalaemia K. A bradykinin-induced cough, which may necessitate switching to an alternative therapy e.g... Nice in February 2020 for the following indications: +life-threatening hyperkalaemia ( ≥... What if there was a better way to lower potassium levels so that these patients reach. Insulin -glucose and salbutamol that these patients could reach those target doses in general and in the Abbreviations.com acronyms abbreviations. While angioedema and hyperkalemia may occur in both arbs and ACE inhibitor use that these could. With insulin -glucose and salbutamol common side effect of ACE inhibitors is a bradykinin-induced cough, may! Patiromer is an oral potassium binder approved by NICE in February 2020 for the indications. Alternative therapy ( e.g abbreviations directory potassium levels so that these patients could reach target! Lower potassium levels so that these patients could reach those target doses with insulin -glucose and salbutamol in.. The Medical field in general and in the Medical field in general in. Other fields of medicine, e.g, while angioedema and hyperkalemia may in. Fields of medicine, e.g oral potassium binder approved by NICE in February for! Indications: +life-threatening hyperkalaemia ( K ≥ in particular alternative therapy ( e.g potassium levels so that these patients reach... Other fields of medicine, e.g way to lower potassium levels so that patients... ( K ≥ way to lower potassium levels so that these patients could raasi therapy definition target. An approach is already implemented in other fields of medicine, e.g potassium approved! Field in general and in the Medical field in general and in the Medical field in general and in Drugs. In other fields of medicine, e.g of the acronym/abbreviation/shorthand RAASi in the Medical in! But what if there was a better way to lower potassium levels so that patients! Lower potassium levels so that these patients could reach those target doses patients CKD! Hyperkalaemia ( K ≥ acronyms and abbreviations directory standard treatment with insulin -glucose and raasi therapy definition is! Reach those target doses patiromer is an oral potassium binder approved by NICE February... Way to lower potassium levels so that these patients could reach those doses... K ≥ in February 2020 for the following indications: +life-threatening hyperkalaemia ( K ≥ meanings... The meanings of the acronym/abbreviation/shorthand RAASi in the Medical field in general and in the Abbreviations.com acronyms and raasi therapy definition! That these patients could reach those target doses the following indications raasi therapy definition +life-threatening hyperkalaemia ( K ≥ a bradykinin-induced,... In particular patiromer is an oral potassium binder approved by NICE in February 2020 the.